Literature DB >> 19937210

Comparison of antimicrobial efficacy of a fixed dose combination of ceftazidime + sulbactam with ceftazidime and sulbactam alone against five bacteria.

S M Shrivastava1, S K Shukla, M Chaudhary.   

Abstract

The efficacy of the agents was evaluated on the basis of minimum inhibitory concentration (MIC) and time-kill curve analysis in Pseudomonas aeruginosa, Staphylococcus aureus, Acinetobacter baumannii, Mycobacterium smegmatis, and Citrobacter braakii; MIC was found to be 0.5, 4.0, 0.015625, 0.0078125, and 0.0625 mg/L in FDC of ceftazidime + sulbactam, respectively, which is lower than ceftazidime and sulbactam individually. Time-kill curve analysis demonstrated maximum killing of bacteria after 4 h. A fixed dose combination of ceftazidime + sulbactam was found to have stronger antibacterial properties than ceftazidime and sulbactam alone at in vitro analysis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19937210     DOI: 10.1007/s12223-009-0054-1

Source DB:  PubMed          Journal:  Folia Microbiol (Praha)        ISSN: 0015-5632            Impact factor:   2.099


  24 in total

1.  Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America.

Authors:  J G Bartlett; S F Dowell; L A Mandell; T M File; D M Musher; M J Fine
Journal:  Clin Infect Dis       Date:  2000-09-07       Impact factor: 9.079

Review 2.  1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America.

Authors:  W T Hughes; D Armstrong; G P Bodey; A E Brown; J E Edwards; R Feld; P Pizzo; K V Rolston; J L Shenep; L S Young
Journal:  Clin Infect Dis       Date:  1997-09       Impact factor: 9.079

3.  Antibiotic synergy against biofilm-forming Pseudomonas aeruginosa.

Authors:  L Cernohorská; M Votava
Journal:  Folia Microbiol (Praha)       Date:  2008-05-15       Impact factor: 2.099

4.  Randomized comparison of sulbactam/cefoperazone with imipenem as empirical monotherapy for febrile granulocytopenic patients.

Authors:  D J Winston; K Bartoni; D A Bruckner; G J Schiller; M C Territo
Journal:  Clin Infect Dis       Date:  1998-03       Impact factor: 9.079

5.  Randomized study of ceftazidime versus gentamicin plus cefotaxime for infections in severe granulocytopenic patients.

Authors:  B E de Pauw; F Kauw; H Muytjens; K J Williams; T Bothof
Journal:  J Antimicrob Chemother       Date:  1983-07       Impact factor: 5.790

6.  The activity of ceftazidime, other beta-lactams, and aminoglycosides against Pseudomonas aeruginosa.

Authors:  K V Rolston; P H Chandrasekar; J L LeFrock; R F Schell
Journal:  Chemotherapy       Date:  1984       Impact factor: 2.544

7.  Ceftazidime therapy of infections caused by Enterobacteriaceae and Pseudomonas aeruginosa.

Authors:  M J Maslow; A Rosenberg; A A Pollock; R A Press; D Silverman; W El-Sadr; A S Richmond; M S Simberkoff; J J Rahal
Journal:  J Antimicrob Chemother       Date:  1983-07       Impact factor: 5.790

8.  In vitro activity of BMY-28142 in comparison with those of other beta-lactam antimicrobial agents.

Authors:  A Tsuji; A Maniatis; M A Bertram; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

9.  Activities of various beta-lactams and aminoglycosides, alone and in combination, against isolates of Pseudomonas aeruginosa from patients with cystic fibrosis.

Authors:  R K Scribner; M I Marks; A H Weber; M M Tarpay; D F Welch
Journal:  Antimicrob Agents Chemother       Date:  1982-06       Impact factor: 5.191

10.  Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum beta-lactam antibiotics.

Authors:  R E Kessler; M Bies; R E Buck; D R Chisholm; T A Pursiano; Y H Tsai; M Misiek; K E Price; F Leitner
Journal:  Antimicrob Agents Chemother       Date:  1985-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.